D
대성미생물
036480KOSDAQ의약품 제조업35.5 / 100
Reference Date: 2026-04-13
Financial Score8.0 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, PER raises overvaluation concerns. Declined 12.6% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Daesung Microbiological is a specialized animal pharmaceutical company founded in 1966, producing and selling over 150 types of products including vaccines, antibiotics, and nutritional supplements. Its revenue is composed of 72% domestic sales and 28% exports, with a growing export share. The company continuously develops new products through R&D aligned with disease trends.
Number of Employees
138people
Average Salary
44.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
47.20Industry Average 14.800.0Point
3.2x industry avg (risky)
PBR
—Industry Average 1.043.5Point
ROE
1.70Industry Average 4.421.0Point
Well below industry avg
Debt Ratio
39.60Industry Average 11.980.0Point
3.3x industry avg (risky)
Trend 2023~20253.5 / 10 points
Revenue Growth Rate
1.0 / 3
Avg ▲1.1% (2-year basis)
Operating Profit Growth Rate
2.5 / 3
Avg ▲10.4% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -1.6% (improving, 2yr)
Detailed News Sentiment
1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50
- Neutral대성미생물, 최승훈 단독 대표이사 체제 변경
대성미생물이 이동규, 이훈구 대표이사 사임 후 최승훈 단독 대표이사 체제로 변경되었다.
Detailed Momentum
52-week position3.0Point
52w lower range (33%)
Current 7,410Won52-week high 9,88052-week low 6,170
1-month return1.0Point
1m -12.62% (falling)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
9 totalPositive 0Neutral 9Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-03-26
- Neutral주식등의대량보유상황보고서(일반)2026-03-26
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-25
- Neutral[기재정정]최대주주변경2026-03-25
- Neutral최대주주변경2026-03-24